Congress Materials – Winter Clinical Hawaii 2026
2026 Winter Clinical Hawaii | Jan 16-21 | Maui, HI
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Durability of Response to the Targeted Oral Peptide Icotrokinra for High-Impact Site Psoriasis: 1-Year ICONIC-TOTAL Findings
Edward Lain, Richard B Warren, Melinda Gooderham, Robert Bissonnette, Yu-Huei Huang, Julien Ringuet, Matthias Hoffmann,7 Andreas Pinter, Joseph F Merola, Jessica Rubens, Dorothy Fan, Ming-Chun Hsu, Shu Li, Ya-Wen Yang, Cynthia DeKlotz, Eingun James Song
Durable Inhibition of Structural Damage Progression and Improvements in Joint Disease Activity With Guselkumab in Active and Erosive Psoriatic Arthritis: Week 48 Results From APEX
Christopher T Ritchlin, Philip J Mease, Laura C Coates, Alexa P Kollmeier, Bei Zhou, Yusang Jiang, Karen Bensley, Koeun Im, Rattandeep Batra, Karissa Lozenski, Steven Fakharzadeh, Soumya D Chakravarty, Proton Rahman, Désirée van der Heijde
Efficacy of Icotrokinra Through Week 24 in Patients With Moderate-to-Severe Plaque Psoriasis: Pooled Results From ICONIC-ADVANCE 1&2
Linda Stein Gold, Benjamin Ehst, Leon Kircik, Paul Wallace, Jill Waibel, Christopher Russo, Cynthia DeKlotz, Shu Li, Fabio Nunes, Katelyn Rowland, April Armstrong
Maintenance of Response With Icotrokinra, a Targeted Oral Peptide, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Randomized Treatment Withdrawal in Adults (Weeks 24-52) and Continuous Treatment in Adolescents (Through Week 52) From the Phase 3, ICONIC-LEAD Trial
Jennifer Soung, Yong (Jonathan) Cui, Robert Bissonnette, Mark Lebwohl, Álvaro González-Cantero, Andreas Pinter, Phoebe Rich, Vimal H. Prajapati, Megan Miller, Joseph Cafone, Jingzhi Jiang, Shu Li, Cynthia Deklotz, Ya-Wen Yang, Andrew E. Pink
SPECTREM: Guselkumab Patient-Reported Outcomes Across Multiple High-Impact Sites in Participants With Low BSA, Moderate Psoriasis: Psoriasis Symptoms and Signs Diary Deep Dive
April Armstrong, Jennifer Soung Brad Glick, Vlada Groysman, Firouzeh Niakosari, Javier Alonzo-Llamazares, Henry Yu, Theodore Alkousakis, Jenny Jeyarajah, Marni Wiseman, Bruce Strober
SPECTREM: Skin Clearance Results Through Week 48 With Guselkumab in Participants With Low Body Surface Area, Moderate Plaque Psoriasis and Palmoplantar Involvement
L. Stein Gold, R. Bissonnette, B. P. Glick, H. Chih-ho Hong, L. Albrecht, T. Alkousakis, K. Rowland, C. Cornejo, J. Jeyarajah, M. G. Lebwohl
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.